• PCA3 - nieinwazyjny wiarygodny test w diagnostyce w kierunku raka prostaty


  • PROFI-LAB - Pierwsze laboratorium w Polsce wykonujące test PCA3


  • Rak prostaty dotyka 1 na 6 mężczyzn
  • 1
  • 2
  • 3

Literatura

W miarę możliwości będziemy się starali na bieżąco umieszczać najświeższe dostępne publikacje dotyczące raka prostaty oraz testów PCA3.

Oto pierwsze z nich:

Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. [Eur Urol 2011]

Salagierski M, Mulders P, Schalken JA. Predicting prostate biopsy outcome using a PCA3-based nomogram in a Polish cohort. [Anticancer Res. 2013 Feb;33(2):553-7.]    praca z udziałem polskiego specjalisty

Salagierski M, Schalken JA. Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion. [J Urol. 2012 Mar;187(3):795-801. doi: 10.1016/j.juro.2011.10.133. Epub 2012 Jan 15].   praca z udziałem polskiego specjalisty

Combination of real-time elastography and urine prostate cancer gene 3 (PCA3) detects more than 97% of significant prostate cancers. Scand J Urol. 2013 Jun;47(3):211-6. doi: 10.3109/00365599.2012.727859. Epub 2012 Oct 4.

Prostate cancer antigen-3 (PCA3) and PCA3-based nomograms in the diagnosis of prostate cancer: an external validation of Hansen's nomogram on a Norwegian cohort. [Scand J Urol 2015]

Comparative evaluation of urinary PCA3 and TMPRSS2: ERG scores and serum PHI in predicting prostate cancer aggressiveness. [Int J Mol Sci 2014]

Real-time PCR PCA3 assay is a useful test measured in urine to improve prostate cancer detection. [Clin Chim Acta 2014]

PCA3-based nomogram for predicting prostate cancer and high grade cancer on initial transrectal guided biopsy. [Prostate, 2015]

Optimizing the clinical utility of PCA3 to diagnose prostate cancer in initial prostate biopsy. [BMC Cancer 2015]

Urinary PCA3 to predict prostate cancer in a cohort of 1015 patients. [2015]

Improved sensitivity and specificity for prostate cancer diagnosis based on the urine PCA3/PSA ratio acquired by sequence‑specific RNA capture [Oncol Rep 2015]

Current biomarkers for diagnosing of prostate cancer [Future Oncol 2015]

Prostate cancer: Urinary PCA3 and TMPRSS2:ERG reduce the need for repeat biopsy. [Nat Rev Urol 2015]

High PCA3 scores are associated to elevated Prostate Imaging Reporting and Data System (PI-RADS) grade and biopsy Gleason Score, at MRI/US fusion software-based targeted prostate biopsy after a previous negative standard biopsy. [BJU Int. 2016 Apr 26. doi: 10.1111/bju.13504. [Epub ahead of print]]

Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score. [Eur Urol. 2016 Apr 20. pii: S0302-2838(16)30071-9. doi: 10.1016/j.eururo.2016.04.012. [Epub ahead of print]]

Clinical Utility of PCA3 and TMPRSS2:ERG Urinary Biomarkers in African American Men Undergoing Prostate Biopsy. [J Urol. 2016 Apr 29. pii: S0022-5347(16)30324-X. doi: 10.1016/j.juro.2016.04.075. [Epub ahead of print]]

Evaluation of PCA3 and multiparametric MRI's: collective benefits before deciding initial prostate biopsy for patients with PSA level between 3-10ng/mL. Int Braz J Urol. 2016 May-Jun;42(3):449-55. doi: 10.1590/S1677-5538.IBJU.2015.0155.

Evaluation of prostate cancer antigen 3 for detecting prostate cancer: a systematic review and meta-analysis. Sci Rep. 2016 May 10;6:25776. doi: 10.1038/srep25776.

A positive Real-Time Elastography (RTE) combined with a Prostate Cancer Gene 3 (PCA3) score above 35 convey a high probability of intermediate- or high-risk prostate cancer in patient admitted for primary prostate biopsy. BMC Urol. 2016 Jul 8;16(1):39. doi: 10.1186/s12894-016-0159-1.

External validation of a PCA-3-based nomogram for predicting prostate cancer and high-grade cancer on initial prostate biopsy. Prostate. 2016 Aug;76(11):1019-23. doi: 10.1002/pros.23197. Epub 2016 May 16.